Similar articles

• Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.

  Gianotti N, Soria A, Galli L, Castagna A, Cernuschi M, Hasson H, Lazzarin A. Gianotti N, et al. J Med Virol. 2004 Feb;72(2):181-6. doi: 10.1002/jmv.10580. J Med Virol. 2004. PMID: 14695657
• Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

  Van Vaerenbergh K. Van Vaerenbergh K. Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
• Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.

  Okano A, Matsuda M, Chiba T, Moriya K, Yamada K, Sugiura W. Okano A, et al. Jpn J Infect Dis. 2002 Apr;55(2):62-5. Jpn J Infect Dis. 2002. PMID: 12082315 No abstract available.
• Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

  Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K. Nuesch R, et al. Clin Infect Dis. 2005 Mar 1;40(5):728-34. doi: 10.1086/427878. Epub 2005 Feb 4. Clin Infect Dis. 2005. PMID: 15714420 Clinical Trial.
• Sustained CD4 responses after virological failure of protease inhibitor-containing therapy.

  Deeks SG, Grant RM. Deeks SG, et al. Antivir Ther. 1999;4 Suppl 3:7-11. Antivir Ther. 1999. PMID: 16021865 Review.